Table 1.

Upfront treatment regimens

Upfront regimen% receiving RT
ABVE-PC 37 (55%) 17 (46%) 
ABVD 12 (18%) 1 (8%) 
OEPA-COPDAC 8 (12%) 4 (50%) 
Stanford V 3 (4%) 7 (70%) 
BEACOPP 2 (3%)  
BV-AVE-PC 2 (3%)  
Nivolumab-AVD 1 (1%)  
Other 2 (3%)  
Upfront regimen% receiving RT
ABVE-PC 37 (55%) 17 (46%) 
ABVD 12 (18%) 1 (8%) 
OEPA-COPDAC 8 (12%) 4 (50%) 
Stanford V 3 (4%) 7 (70%) 
BEACOPP 2 (3%)  
BV-AVE-PC 2 (3%)  
Nivolumab-AVD 1 (1%)  
Other 2 (3%)  

ABVE-PC, doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; AVD, doxorubicin, vinblastine, dacarbazine; BEACOPP, bleomycin, etoposide, cyclophosphamide, vincristine, prednisone, procarbazine; BV-AVE-PC, brentuximab vedotin, doxorubicin, vincristine, etoposide, prednisone, cyclophophamide; OEPA-COPDAC, vincristine, etoposide, prednisone, doxorubicin, cyclophosphamide, vincristine, prednisone, dacarbazine; Stanford V, mechlorethamine, etoposide, adriamycin, bleomycin, vincristine, vinblastine, prednisone.

Close Modal

or Create an Account

Close Modal
Close Modal